# A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Source: https://onco.cc/trials/nct07164170/  
OnCo record `nct07164170` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Glecirasib in non-small-cell lung cancer and small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.

## Summary

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib is a phase 2 interventional study registered as NCT07164170 by Abbisko Therapeutics Co, Ltd, with 86 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK043 in combination with Glecirasib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07164170
- Phase: 2
- Setting: An Open-label Phase II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ABSK043 in Combination With Glecirasib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring a KRAS G12C Mutation
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 86

## Sources

- ClinicalTrials.gov NCT07164170: https://clinicaltrials.gov/study/NCT07164170

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Glecirasib](https://onco.cc/drugs/glecirasib/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct07164170.json